No description available.

Thesis (M. Phil.)--University of Hong Kong, 2009. / Includes bibliographical references (p. 92-108) Also available in print.

Thesis (Ph. D.)--University of Hong Kong, 1999. / Includes bibliographical references (leaves 118-138).

Thesis (Ph. D.)--Rutgers University, 2007. / "Graduate Program in Biomedical Engineering." Includes bibliographical references.

COSTA, D. V. S. C. Papel da via S100β/RAGE/NFκB na patogênese da mucosite intestinal experimental por 5-fluorouracil: regulação de células gliais e de neurônios entéricos. 2016. 155 f. Dissertação (Mestrado em Farmacologia) - Faculdade de Farmácia, Odontologia e Enfermagem, Universidade Federal do Ceará, Fortaleza, 2016. / Submitted by Erika Fernandes (erikaleitefernandes@gmail.com) on 2016-06-08T13:56:23Z No. of bitstreams: 1 2016_dis_dvscosta.pdf: 7653770 bytes, checksum: 657b91914f13efe21ff21ef656775a6b (MD5) / Approved for entry into archive by Erika Fernandes (erikaleitefernandes@gmail.com) on 2016-06-08T13:56:32Z (GMT) No. of bitstreams: 1 2016_dis_dvscosta.pdf: 7653770 bytes, checksum: 657b91914f13efe21ff21ef656775a6b (MD5) / Made available in DSpace on 2016-06-08T13:56:32Z (GMT). No. of bitstreams: 1 2016_dis_dvscosta.pdf: 7653770 bytes, checksum: 657b91914f13efe21ff21ef656775a6b (MD5) Previous issue date: 2016-01-29 / 5-Fluorouracil (5-FU) promotes intestinal mucositis and motility alterations. The mucositis affect about 40% of patients receiving 5-FU and there are reports of patients presenting mucositis after the first dose. Under other inflammatory conditions, the S100β protein is involved in the RAGE activation with subsequent NFκB translocation to the nucleus and transcription of TNF-α and iNOS. The enteric glial cells through several mediators, such as S100β, interact with the intestinal epithelial cells and enteric neurons. Therefore, the aim of this study was investigate the effect of 5-FU in the enteric glial cells and neurons, as well as study the role of the via S100β/RAGE/NFκB in the pathogenesis of the experimental intestinal mucositis. Swiss male mice received saline (control, 0.9%, i.p.) or 5-FU (450 mg/Kg, i.p., single dose). After 24h, mice were treated with pentamidine, a S100β inhibitor (P0.8 mg/Kg +5FU; P4 mg/Kg +5FU; or only P4mg/Kg, i.p.) during two days and euthanized on the fouth day of the experimental protocol. The segments of the small intestine and colon were collected to analyze the following parameters: weight loss; histological alterations; expression of enteric glial cells (GFAP e S100β) and neuronal (HuC/D) marker using immunohistochemistry; expression of iNOS and co-localization of GFAP and Iba-1, and HuC/D and RAGE or NFκB NLS using immunofluorescence; protein expression of S100β, NFκB p65, iNOS and RAGE by Western Blotting; genic expression of GFAP, S100β and iNOS using qPCR; The levels of nitrite/nitrate, GSH, MDA, TNF-α and IL6 by ELISA. The 5-FU promoted reduction of intestinal villus, loss of crypts integrity, intense inflammatory cell infiltrate and hypertrophy of the myenteric plexus, as well as increased the GFAP and S100β immunostaining and diminished the HuC/D immunostaining. 5-FU was also able to elevate RAGE and NFκB NLS immunostaining in the enteric neurons and Iba-1 in the intestine, as well as, augmented the protein expression of S100β, RAGE, NFκB p65 and iNOS, and the genic expression of S100β, GFAP and iNOS. Furthermore, it enhanced the MDA, nitrite/nitrate and proinflammatory cytokines (TNF-α e IL-6) levels in the small intestine and colon. The S100β inhibition was able to revert these changes promoted by 5-FU. We provide evidence that 5-FU promote reactive gliosis, leading reduction of the enteric neurons via S100β/RAGE/NFκB. Together, these results suggest that S100β is a mediator important involved in the pathogenesis of the 5-FU-induced intestinal mucositis. / O 5-Fluorouracil (5-FU) promove mucosite intestinal e alterações da motilidade. A mucosite atinge cerca de 40% dos pacientes em tratamento com 5-FU e há relatos de pacientes que a apresentam na primeira dose administrada. Em outras condições inflamatórias, a proteína S100β está envolvida na ativação de RAGE com consequente translocação de NFκB para o núcleo e transcrição de TNF-α e de iNOS. As células gliais entéricas por meio de S100β, interagem com as células epiteliais intestinais e com os neurônios entéricos. Nesse contexto, o objetivo deste estudo é investigar o efeito do 5-FU nas células gliais e nos neurônios entéricos, bem como estudar o papel da via S100β/RAGE/NFκB na patogênese da mucosite intestinal induzida por esse quimioterápico. Os camundongos Swiss machos receberam salina (0,9%, i.p.) ou 5-FU (450 mg/Kg, i.p. dose única). Após 24h da administração do quimioterápico, administrou-se pentamidina, inibidor de S100β (P0,8 mg/Kg +5FU; P4 mg/Kg +5FU; ou somente P4mg/Kg, i.p.) durante dois dias e os animais foram eutanasiados no quarto dia do protocolo experimental. Os segmentos do intestino delgado e do cólon foram coletados para a análise dos seguintes parâmetros: perda ponderal; alterações histológicas; expressão de marcador de células gliais (GFAP e S100β) e neuronal (HuC/D) por imunohistoquímica; imunofluorescência para iNOS e dupla marcação para GFAP e Iba-1, e para HuC/D e RAGE ou NFκB NLS; expressão proteica de S100β, NFκB p65, iNOS e RAGE por Western Blotting; expressão gênica de GFAP, S100β e iNOS por qPCR; e dosagem dos níveis de nitrito/nitrato, GSH, MDA, TNF-α e IL6. O 5-FU promoveu redução das vilosidades intestinais, perda da integridade das criptas, intenso infiltrado de células inflamatórias e hipertrofia do plexo mioentérico, bem como aumento da área imunomarcada para GFAP e S100β e redução de HuC/D. Esse quimioterápico também foi capaz de elevar a imunomarcação para RAGE e NFκB NLS nos neurônios entéricos e aumentou a imunomarcação para Iba-1, assim como elevou a expressão proteica de S100β, RAGE, NFκB p65 e iNOS, e a expressão gênica de S100β, GFAP e iNOS. Além disso, aumentou os níveis de MDA, de nitrito/nitrato e de citocinas pró-inflamatórias (TNF-α e IL-6) no intestino delgado e no cólon. Ao passo que a inibição de S100β foi capaz de reverter essas alterações promovidas por 5-FU. Conclui-se que 5-FU promove gliose reativa, resultando em redução dos neurônios entéricos pela ativação da via S100β/RAGE/NFκB. Adicionalmente, S100β demonstrou ser um importante mediador envolvido na patogênese da mucosite intestinal.

No description available.

No description available.

Na,K-ATPase é uma proteína de membrana que tem como função manter o equilíbrio osmótico nas células pela hidrólise de ATP. A ouabaína (OUA) se liga a Na,K-ATPase e é capaz de ativar cascatas de sinalização. As subunidades a da Na,K-ATPase possuem 4 isoformas que são distribuídas de forma diferenciada nos tecidos. As células da glia são importantes na resposta contra lesões no cérebro e também controlam a inflamação. Dados na literatura mostram que a OUA tem efeito protetor em alguns tipos de dano. O objetivo do estudo é avaliar a função da isoforma a2 na cultura de células da glia em resposta à OUA e ao LPS. Nós investigamos a ação da OUA em diversas concentrações e LPS (1g/mL) na viabilidade celular (LDH) e proliferação celular (MTT). O LPS foi utilizado como modelo de inflamação e uma das perguntas era se o tratamento prévio com OUA, seria capaz de reverter a ativação do fator de transcrição NF-kB que está envolvido com inflamação. O pré-tratamento com OUA diminuiu a ativação do NF-kB induzida pelo LPS. Após, nós silenciamos a isoforma a2 das células da glia com RNAi. Os nossos dados mostram que o pré-tratamento com OUA reverte o efeito na ativação do NF-kB causado pelo LPS. Provavelmente, a isoforma a2 está relacionada com alguma via de sinalização que interage com a via do LPS. / Na,K-ATPase is a conserved membrane protein which maintains the osmotic balance in the cell by the hydrolysis of ATP. Ouabain (OUA) binds to Na,K-ATPase and it can activate signaling pathways. The a subunits of Na,K-ATPase have 4 isoforms which are distributed in a different pattern in the tissues. Glial cells have an important role in the response against injury and they also control inflammation. Some data have reported that OUA can protect against some types of injury. The aim of this study is to evaluate the role of a2 isoform in glial cells in response to OUA and LPS stimulus. We investigated the action of OUA and LPS in cell viability (LDH) and cell proliferation (MTT). LPS was used as a model of inflammation and one of our questions was if the treatment with OUA before LPS was capable of reduce the activation of the transcription factor NF-kB which is involved in inflammation. The pre-treatment with OUA decreased the NF-kB activation induced by LPS. We also silenced the a2 isoform in culture glial cells with iRNA. Taken together our data showed that OUA pretreatment reversed the NF-kB activation induced by LPS in primary cultures of glial cells from mice. Probably,the a2 isoform is related with some signaling pathway that interacts with the LPS pathway.

Lai, Ching Janice. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2005. / Includes bibliographical references (leaves 148-168). / Abstracts in English and Chinese. / Abstract --- p.i / Abstract in Chinese --- p.iii / Acknowledgements --- p.v / Table of Content --- p.vi / List of Tables --- p.x / List of Figures --- p.xi / Abbreviations --- p.xii / Chapter Chapter 1 --- Introduction --- p.1 / Chapter 1.1 --- General Introduction --- p.1 / Chapter 1.2 --- Nervous System and the Blood-Brain-Barrier --- p.3 / Chapter 1.3 --- Glial cells --- p.3 / Chapter 1.4 --- Studying Astrocyte Responses As a New Direction in Neuroscience --- p.4 / Chapter 1.5 --- The Roles of Astrocyte in the CNS --- p.5 / Chapter 1.5.1 --- Energy-Dependent Communication Between Neurons and Astrocytes --- p.7 / Chapter 1.5.2 --- Strategies for Metabolic Exchange Between Astrocytes and Neurons --- p.8 / Chapter 1.5.2.1 --- Provision of Energy Metabolites to Neurons by Astrocytes --- p.9 / Chapter 1.5.2.2 --- Glucose Transporters in the CNS --- p.10 / Chapter 1.5.2.3 --- The Lactate Shuttle Hypothesis --- p.12 / Chapter 1.5.2.4 --- The Regulation of Glucose Uptake at the Blood-Brain-Barrier (BBB) by the Activity of Neurons --- p.14 / Chapter 1.5.3 --- Alternation of Energy Metabolism in Neuropathy --- p.15 / Chapter 1.5.3.1 --- Ketone Body Shuttle Hypothesis --- p.15 / Chapter 1.5.3.2 --- The Utilization of Free Fatty Acids by the Brain --- p.17 / Chapter 1.5.4 --- The Provision of Neurotrophic Factors to Neurons by Astrocytes --- p.17 / Chapter 1.5.4.1 --- Neurotrophins --- p.18 / Chapter 1.5.4.1.1 --- Relationship Between Neurotrophins and Glucose --- p.20 / Chapter 1.5.4.2 --- S100B --- p.21 / Chapter 1.5.5 --- Astrocytic Cholesterol in Astrocytes as a Neurotrophic Factor --- p.22 / Chapter 1.6 --- Neuroprotective Effect of Glucose vi - --- p.23 / Chapter 1.7 --- Diseases Associated with Decreased Glucose Transport at the BBB --- p.24 / Chapter 1.7.1 --- Glucose Transporter Type 1 Deficiency Syndrome (GlutlDS) --- p.24 / Chapter 1.7.2 --- Hypoglycemia with Insulin Therapy for Diabetes Patients --- p.24 / Chapter 1.8 --- Aims and Hypothesis of Study --- p.26 / Chapter Chapter 2. --- 2 Materials and Methods --- p.27 / Chapter 2.1 --- Materials --- p.27 / Chapter 2.1.1 --- Cell Culture --- p.27 / Chapter 2.1.1.1 --- Cells --- p.27 / Chapter 2.1.1.1.1 --- C6 cells --- p.27 / Chapter 2.1.1.1.2 --- Primary Astrocytes --- p.27 / Chapter 2.1.1.2 --- Cell Culture Reagent --- p.27 / Chapter 2.1.2 --- Study of Growth Properties --- p.31 / Chapter 2.1.2.1 --- Equipment for Growth Curve Construction --- p.31 / Chapter 2.1.2.2 --- Reagents for Flow Cytometry --- p.32 / Chapter 2.1.2.3 --- Reagents for 3H-thymidine Incorporation Assay --- p.32 / Chapter 2.1.3 --- Study of Neurotrophic Properties --- p.33 / Chapter 2.1.3.1 --- Determination of Neurotrophic Factor Productions --- p.33 / Chapter 2.1.3.1.1 --- Reagents and Buffers for Northern Blot Analysis --- p.33 / Chapter 2.1.3.2 --- Reagents and Buffers for Western Blot Analysis --- p.43 / Chapter 2.1.3.2.1 --- Protein Assay --- p.43 / Chapter 2.1.3.2.2 --- Reagents for SDS Polyacrylamide Electrophoresis of Proteins --- p.44 / Chapter 2.1.3.2.3 --- Reagents for the Transfer of Protein to Membrane and Signal Detection --- p.47 / Chapter 2.1.4 --- Study of Lipid in Glial cells --- p.50 / Chapter 2.1.4.1 --- Determination of Genes Expression in Lipid Metabolism --- p.50 / Chapter 2.1.4.2 --- Reagents for Determination of Cholesterol and Fatty Acid Levels by Gas Chromatography --- p.50 / Chapter 2.2 --- Methods --- p.54 / Chapter 2.2.1 --- Cell culture --- p.54 / Chapter 2.2.1.1 --- Maintenance of C6 cells --- p.54 / Chapter 2.2.1.2 --- Primary Culture of Rat Astrocytes --- p.54 / Chapter 2.2.2 --- Study of Growth Properties of Glial Cells vii - --- p.56 / Chapter 2.2.2.1 --- Construction of cell growth curve --- p.56 / Chapter 2.2.2.2 --- Flow Cytometric Analysis of Cell Cycle Profile --- p.56 / Chapter 2.2.2.3 --- Measurement of DNA Synthesis --- p.57 / Chapter 2.2.3 --- Study of Neurotrophic Properties --- p.58 / Chapter 2.2.3.1 --- Determination of Neurotrophic Facotor Production --- p.58 / Chapter 2.2.3.1.1 --- Northern Blot Analysis --- p.58 / Chapter 2.2.3.1.2 --- Western Blot Analysis --- p.67 / Chapter 2.2.3.2 --- Determination of Gene Expression in Lipid Metabolism --- p.72 / Chapter 2.2.3.2.1 --- Northern Blot Analysis --- p.72 / Chapter 2.2.3.2.2 --- RT-PCR --- p.72 / Chapter 2.2.3.3 --- Study of Lipid Profiles in Glial Cells --- p.73 / Chapter 2.2.3.3.1 --- Sample preparation --- p.73 / Chapter 2.2.3.3.2 --- Total Cholesterol Determination --- p.73 / Chapter 2.2.3.3.3 --- Total Fatty Acid Determination --- p.75 / Chapter 2.2.3.3.4 --- Quantification of Proteins --- p.76 / Chapter 2.2.4 --- Statistical Analysis --- p.77 / Chapter Chapter 3 --- Results --- p.78 / Chapter 3.1 --- The effects of glucose deficiency on cell proliferation --- p.78 / Chapter 3.1.1 --- Direct Cell Count Assay --- p.78 / Chapter 3.1.2 --- Flow Cytometry Assay --- p.83 / Chapter 3.1.3 --- 3H-Thymidine Uptake Assay --- p.85 / Chapter 3.2 --- The Effects of Glucose Deficiency on Neurotrophic Properties of Glial Cells --- p.87 / Chapter 3.2.1 --- The Effects of Glucose Deficiency on mRNA and Protein Expressions of Neurotrophins --- p.88 / Chapter 3.2.1.1 --- Northern Blot Assays --- p.88 / Chapter 3.2.1.2 --- Western Blot Assays --- p.93 / Chapter 3.2.2 --- The Effects of Glucose Deficiency on Lipid Homeostasis --- p.96 / Chapter 3.2.2.1 --- Northern Blot Assays --- p.96 / Chapter 3.2.2.2 --- Gas Chromatography Assays --- p.101 / Chapter 3.2.2.2.1 --- Cholesterol Analyses --- p.102 / Chapter 3.2.2.2.2 --- Fatty Acid Analyses --- p.105 / Chapter Chapter 4 --- Discussion --- p.115 / Chapter 4.1 --- The in vitro Model of Hypoglycorrhachia --- p.115 / Chapter 4.2 --- Decreased Glucose Level Triggers Changes of Gial Cells Proliferation --- p.117 / Chapter 4.3 --- Expression of Neurotrophic Factor under Glucose Deficiency viii - --- p.120 / Chapter 4.3.1 --- Alteration of the Expression of Neurotrophins --- p.120 / Chapter 4.3.1.1 --- NGF --- p.122 / Chapter 4.3.1.2 --- BDNF --- p.123 / Chapter 4.3.1.3 --- NT-3 --- p.126 / Chapter 4.3.1.4 --- NT-4/5 --- p.128 / Chapter 4.3.2 --- Alteration of the mRNA Expression of Calcium Binding ProteinS100B --- p.128 / Chapter 4.4 --- Alteration of Lipid Metabolism in Decreased Glucose Supply --- p.130 / Chapter 4.4.1 --- Up-regulation of ApoE mRNA Expression in Glucose Deficiency --- p.133 / Chapter 4.4.2 --- Cholesterol Homeostasis in Glial Cells --- p.133 / Chapter 4.4.3 --- Fatty Acids Homeostasis in Glial Cells --- p.135 / Chapter 4.4.4 --- Decreased Ketone Bodies synthesis in Glucose Deficiency --- p.143 / Chapter 4.5 --- Limitations of the Current Study --- p.144 / Chapter 4.6 --- Future Directions --- p.145 / Chapter Chapter 5 --- Conclusion --- p.147 / References --- p.148 / Appendix --- p.169

Diss. (sammanfattning) Stockholm : Karol. inst., 2004. / Härtill 4 uppsatser.